Health Care · Pharmaceutical Preparations

VNDA Vanda Pharmaceuticals Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1347178146 filings
Russell 2000

VNDA at a glance

Vanda Pharmaceuticals Inc. (VNDA, SEC CIK 1347178) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 20, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Vanda Pharmaceuticals Inc. (VNDA) reported revenue of $216.1 million (up 8.7% from FY2024) and a net loss of $220.5 million. Diluted EPS was -$3.74.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Vanda Pharmaceuticals Inc. (VNDA) shares worth $152.3 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Duncan Charles Cliff on November 5, 2026 of 5,803 shares at $3.80 per share.
  • In the last 90 days, VNDA insiders reported 3 open-market purchases ($38K) and 0 open-market sales ($0) on Form 4, a net purchase of $38K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$216.1M
+8.7% vs prior year
Insiders · 90 days
3 buys · 0 sells
Net +$38K
13F holders
25 funds
$152.3M · +0 vs prior quarter
Latest 8-K
Nov 20, 2026
Item 1.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $69.8M, up 24% YoY from $56.3M
  • Fanapt best performer, sales $38.8M, up 24% YoY; NEREUS $1.6M launch revenue
  • Gross margin 94.0% vs 94.7% YoY, based on revenue and cost of goods sold
  • Cash, equivalents and securities $140.5M vs $263.8M; operating cash outflow nine months $109.7M
  • Outlook: BYSANTI launch expected Q4 2026; HETLIOZ sales may decline significantly amid generic competition

Risk Factors

  • No material risk-factor changes from the December 31, 2025 Form 10-K
  • Carried-forward business risk: factors could materially adversely affect operations, financial condition, and common-stock price
  • Filing identifies no newly triggered regulatory, legal, operational, competitive, market, or financial risk changes

AI summary of the VNDA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 20, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Vanda settled MSN’s patent challenge to generic HETLIOZ LQ oral suspension
  • MSN licensed to launch its generic in Q1 2040, subject to earlier-entry exceptions
Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $69.8M, up 24% YoY, led by Fanapt $38.8M and HETLIOZ $21.7M including $7.0M of timing-related shipments
  • Operating expenses $93.3M, down 18% sequentially, supporting management’s expectation for further cost reductions

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results covered quarter ended September 30, 2026
  • Earnings call and press release issued October 28, 2026
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $50.5M, down 4%; Fanapt sales rose 23% to $36.0M, offset by HETLIOZ decline
  • Net loss widened to $62.5M, or $1.04 per share, from $27.2M as R&D and launch spending increased

Item 2.02: Results of Operations and Financial Condition

  • Vanda announced quarterly results for the period ended June 30, 2026
  • Earnings call and accompanying press release dated August 5, 2026

AI summaries of VNDA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for VNDA

Don't miss the next VNDA filing

  • Alerts as it files. A push when VNDA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut VNDA, by share count.
  • Ask anything. An AI agent that reads every VNDA filing and answers with sources.

VNDA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Duncan Charles CliffBuyNov 5, 2026$3.80
Duncan Charles CliffBuyNov 4, 2026$3.82
Duncan Charles CliffBuyNov 3, 2026$3.80
DUGAN RICHARD WAJun 4, 2026-
Honore TageAJun 4, 2026-
Mitchell Stephen RayAJun 4, 2026-
McGuire Daniel PatrickAJun 4, 2026-
Ward Anne SempowskiAJun 4, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$198.8M$216.1M
Operating Income--$40.7M-$151.2M
Net Income$2.5M-$18.9M-$220.5M
Op. Margin--20.5%-70.0%
Net Margin--9.5%-102.0%
Balance Sheet
Total Assets-$656.2M$488.9M
Equity$544.9M$538.5M$327.2M
ROE0.5%-3.5%-67.4%
Per Share
EPS$0.04$-0.33$-3.74
Cash Flow
Operating CF$12.8M-$15.8M-$109.4M
CapEx-$490K$998K

Source: XBRL data in Vanda Pharmaceuticals Inc. (VNDA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate VNDA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
VNDA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$152.3M
Q2 202625$188.1M
Q1 202624$192.8M
Q4 202523$216.5M
Q3 202524$139.7M
Q2 202526$135.5M
Q1 202523$81.8M
Q4 202419$70.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

VNDA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 20, 2026Analysis-
4Nov 5, 2026--
10-QOct 29, 2026Analysis
8-KOct 28, 2026Analysis-
SC 13GAug 19, 2026-
SC 13GAug 13, 2026-
10-QAug 6, 2026Analysis
8-KAug 5, 2026Analysis-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 5, 2026Analysis
4May 20, 2026-
SC 13GMay 12, 2026-
10-QMay 7, 2026Analysis
8-KMay 6, 2026Analysis
4Apr 24, 2026--
8-KApr 22, 2026Analysis-
8-KApr 2, 2026Analysis-
8-KMar 10, 2026Analysis-
4Mar 4, 2026--

Related Health Care companies

All Health Care →

VNDA SEC filings: frequently asked questions

Are VNDA insiders buying or selling?

In the last 90 days, Vanda Pharmaceuticals Inc. (VNDA) officers, directors and 10% owners reported 3 open-market purchases worth $38,094 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold VNDA stock?

As of September 30, 2026, the largest Vanda Pharmaceuticals Inc. (VNDA) holders among the 13F filers tracked by SignalX were BlackRock ($41.6 million), Millennium Management ($20.9 million), Renaissance Technologies LLC ($16.2 million), State Street Corp ($14.8 million), Vanguard Capital Management LLC ($12.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was VNDA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Vanda Pharmaceuticals Inc. (VNDA) reported revenue of $216.1 million (up 8.7% from FY2024) and a net loss of $220.5 million. Diluted EPS was -$3.74. The figures come from the XBRL data in the 10-K.

What did VNDA report in its latest 8-K?

Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K on November 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Vanda settled MSN’s patent challenge to generic HETLIOZ LQ oral suspension.

What are the latest VNDA SEC filings?

Vanda Pharmaceuticals Inc. (VNDA) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 20, 2026 and a Form 4 insider filing on November 5, 2026.

What is VNDA's SEC CIK number?

Vanda Pharmaceuticals Inc. (VNDA)'s SEC Central Index Key (CIK) is 1347178. EDGAR lists every VNDA filing under that number.

Ask anything about VNDA

The research agent reads VNDA's filings, financials, insider trades and 13F holders, then answers with sources.